Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses a randomized phase III placebo-controlled trial that explored apatinib as a treatment for patients with advanced gastric cancer.

Bendell says apatinib is an oral, VEGFR-2 TKI. During the trial, the drug was studied in Chinese patients as second-line therapy for patients with metastatic gastric cancer. The study found that there was a statistically significant improvement in overall survival in the apatinib arm versus the placebo arm, Bendell says.

The toxicity profile is similar to other VEGFR TKIs but patients in this study also experienced fatigue. Bendell is hopeful that there will be more studies examining the efficacy of apatinib in the United States.

View more from the 2014 World GI Congress

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Bendell Discusses a Phase III Study of Apatinib in Gastric Cancer